Financial News
Latest News about INNPF
Recent news which mentions INNPF
Cannabinoid Leader Innocan Pharma's Q3: 174% YoY Revenue Growth
November 21, 2024
From Benzinga
From Benzinga
This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain
April 23, 2024
From Benzinga
534% Revenue Surge Unveiled By Israeli CBD-Focused Pharma Company, Exceeding Expectations
April 02, 2024
From Benzinga
CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval
February 13, 2024
From Benzinga
From Benzinga
More Cannabis Funding For FDA And Product Expansion: How This Pharma Tech Company Is Doing It
October 23, 2023
Tickers
INNPF
From Benzinga
CBD-Focused Pharma Co. Seeks Funding To Revolutionize Healthcare
September 21, 2023
From Benzinga
Innocan Pharma's Q2 2023 Reports Gross Profit Growth Driven By Robust Subsidiary Sales
August 28, 2023
Tickers
INNPF
From Benzinga
Cannabis Stock Gainers And Losers From August 25, 2023
August 25, 2023
From Benzinga
From Benzinga
From Benzinga
Cannabis Stock Gainers And Losers From August 14, 2023
August 14, 2023
From Benzinga
Cannabis Stock Gainers And Losers From August 11, 2023
August 11, 2023
From Benzinga
Innocan Pharma To Secure Up To $3M Via Private Placement Of Units At A 9% Prime Above Share Price
July 25, 2023
Tickers
INNPF
From Benzinga
Cannabis Stock Movers For July 21, 2023
July 21, 2023
From Benzinga
Can Liposomal CBD Injection Help Dogs With Polyarthritis? Innocan Pharma Reports Clinical Success
February 21, 2023
Tickers
INNPF
From Benzinga
Innocan Pharma Q3 Revenue Grows 700% YoY, Here Is What You Need To Know
November 29, 2022
Tickers
INNPF
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
